Evidence map›Paper›PMID 37626267›Full record

ArticleBone marrow transplantation2023

Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients.

Angela Lee, Corinne Badgley, Mimi Lo, Marisela Tan Banez, Larissa Graff, Lloyd Damon, Thomas Martin, John Dzundza, Melisa Wong, Rebecca Olin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Angela LeeDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA. Angela.Lee4@ucsf.edu.ORCID http://orcid.org/0000-0002-7138-7308
Corinne BadgleyDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA.
Mimi LoDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA.
Marisela Tan BanezDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7406-286X
Larissa GraffDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA.
Lloyd DamonDivision of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7934-5321
Thomas MartinDivision of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.
John DzundzaDivision of Hospital Medicine, University of California, San Francisco, San Francisco, CA, USA.
Melisa WongDivision of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.
Rebecca OlinDivision of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5060-0384
University of California, San Francisco · USSan Francisco General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic cell transplant (HCT) recipients are at risk for thromboembolic and bleeding complications. There is limited evidence regarding the optimal approach to managing venous thromboembolism (VTE) prophylaxis in hospitalized patients undergoing HCT. In this retrospective cohort study, we evaluated the incidence of bleeding and VTE events in hospitalized HCT patients who received VTE prophylaxis per our institution's VTE Prophylaxis Protocol (VPP), with either enoxaparin 40 mg subcutaneously daily or heparin 5 000 units subcutaneously twice daily, compared to historical controls who did not receive VTE prophylaxis. The primary outcome was a composite of major bleeding events, clinically relevant non-major bleeding (CRNMB), and minor bleeding. The secondary outcome was a composite of VTE events. A total of 614 patients were evaluated, including 278 prior to and 336 after implementation of VPP. VTE prophylaxis resulted in no difference in bleeding events (15.1% in the pre-VPP group vs. 14.6% in the post-VPP group, p = 0.86) or composite of major and CRNMB events (0.72% vs. 0.30%, p = 0.59). There was a trend toward lower incidence of VTE events in the post-VPP group which did not reach statistical significance (8.6% vs. 6.0%, p = 0.20). We conclude that VTE prophylaxis does not pose additional bleeding risk in HCT patients.

Indexed as

Hematopoietic Stem Cell TransplantationVenous ThromboembolismAnticoagulantsHemorrhageHeparinHumansRetrospective StudiesAnticoagulantsHeparin

Identifiers

PMID37626267
PMCPMC10622316
OpenAlexW4386163410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.